NEW YORK (GenomeWeb) – Meridian Bioscience Thursday morning reported a 3 percent uptick in fiscal second quarter revenues bolstered by growth in its Diagnostics segment and particularly sales of its Illumigene product line.

For the three months ended March 31, the Cincinnati-based diagnostics and life science research tools firm reported revenues of $51.5 million compared to $50.1 million in fiscal Q2 2014, and beating analysts' consensus estimate of $50.4 million. On a currency-neutral basis, revenues increased 6 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.